| Chronic Obstructive Airway Disease

Bevespi Aerosphere vs Nucala

Side-by-side clinical, coverage, and cost comparison for chronic obstructive airway disease.
Deep comparison between: Bevespi Aerosphere vs Nucala with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.
Safety signalsNucala has a higher rate of injection site reactions vs Bevespi Aerosphere based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Nucala but not Bevespi Aerosphere, including UnitedHealthcare
Sign up to reveal the full AI analysis
Bevespi Aerosphere
Nucala
At A Glance
Oral inhalation
Twice daily
LAMA/LABA combination
SC injection
Every 4 weeks
IL-5 antagonist
Indications
  • Chronic Obstructive Airway Disease
  • Asthma
  • Chronic rhinosinusitis with multiple nasal polyps
  • Chronic Obstructive Airway Disease
  • Eosinophilic granulomatosis with polyangiitis
  • Hypereosinophilic syndrome
Dosing
Chronic Obstructive Airway Disease 2 inhalations (glycopyrrolate 18 mcg and formoterol fumarate 9.6 mcg) twice daily in the morning and evening by oral inhalation; do not exceed two inhalations twice daily.
Asthma (>=12 years), Chronic rhinosinusitis with multiple nasal polyps, Chronic Obstructive Airway Disease 100 mg SC once every 4 weeks.
Asthma (6-11 years) 40 mg SC once every 4 weeks.
Eosinophilic granulomatosis with polyangiitis, Hypereosinophilic syndrome 300 mg SC once every 4 weeks, administered as 3 separate 100 mg injections at least 5 cm apart.
Contraindications
  • Use of a long-acting beta2-adrenergic agonist (LABA), including formoterol fumarate, without an inhaled corticosteroid in patients with asthma
  • Hypersensitivity to glycopyrrolate, formoterol fumarate, or any component of the product
  • History of hypersensitivity to mepolizumab or excipients in the formulation
Adverse Reactions
Most common (>=2%) Cough, urinary tract infection
Serious Paradoxical bronchospasm, hypersensitivity reactions including anaphylaxis, cardiovascular effects, worsening of narrow-angle glaucoma, worsening of urinary retention
Postmarketing Hypersensitivity, urinary retention
Most common (>=3%) headache, injection site reaction, back pain, fatigue, oropharyngeal pain, arthralgia, diarrhea, urinary tract infection, cough, pruritus, eczema
Serious herpes zoster
Postmarketing hypersensitivity reactions including anaphylaxis
Pharmacology
BEVESPI AEROSPHERE combines glycopyrrolate, a long-acting anticholinergic (LAMA) that inhibits M3 muscarinic receptors in airway smooth muscle to produce bronchodilation, with formoterol fumarate, a long-acting selective beta2-adrenoceptor agonist (LABA) that stimulates adenyl cyclase to increase cyclic AMP, relaxing bronchial smooth muscle and inhibiting mediator release from mast cells.
Mepolizumab is an IL-5 antagonist (IgG1 kappa) that binds IL-5 with high affinity, blocking its binding to the alpha chain of the IL-5 receptor complex on eosinophils, thereby inhibiting IL-5 signaling and reducing eosinophil production and survival.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Bevespi Aerosphere
  • Covered on 5 commercial plans
  • PA (4/12) · Step Therapy (5/12) · Qty limit (9/12)
View full coverage details ›
Nucala
  • Covered on 5 commercial plans
  • PA (11/12) · Step Therapy (11/12) · Qty limit (11/12)
View full coverage details ›
UnitedHealthcare
Bevespi Aerosphere
  • Covered on 4 commercial plans
  • PA (0/8) · Step Therapy (0/8) · Qty limit (6/8)
View full coverage details ›
Nucala
  • Covered on 4 commercial plans
  • PA (6/8) · Step Therapy (6/8) · Qty limit (6/8)
View full coverage details ›
Humana
Bevespi Aerosphere
  • Covered on 0 commercial plans
  • PA (3/3) · Step Therapy (2/3) · Qty limit (3/3)
View full coverage details ›
Nucala
  • Covered on 0 commercial plans
  • PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
View full coverage details ›
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Bevespi Aerosphere.
Cost estimate not availableAccessia Health: Asthma - Private Insurance
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
  • Verify eligibility with the payer.
  • Pull the right PA forms directly from the payer.
  • Submit, track & send live updates to your dashboard.
Utilize patient records to autofill forms with our AI in seconds.
Free to start · HIPAA compliant
Next Steps for Your Patient
Bevespi AerosphereView full Bevespi Aerosphere profile
NucalaView full Nucala profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.